COVID-19 – TERAVOLT Study

The global TERAVOLT registry, initiated in March 2020, aims to provide outcome data specific to patients with thoracic cancer, who contracted COVID-w19. The data collected will, hopefully, guide disease management and define factors influencing associated morbidity and mortality. The Lung Ambition Alliance has recently announced that it is providing new funding for TERAVOLT.